MNKD

MannKind Corporation is a biopharmaceutical innovator headquartered in Westlake Village, California, focusing on advanced inhaled therapeutics specifically for endocrine disorders and orphan lung diseases. Leveraging its proprietary Technosphere® platform, the company markets Afrezza, a novel inhaled insulin that aims to enhance glycemic control for diabetes patients, addressing significant unmet medical needs in insulin delivery. With a commitment to pioneering innovative pulmonary delivery systems, MannKind is strategically positioned to redefine treatment paradigms in diabetes management and respiratory therapeutics, potentially offering critical advantages over conventional methods. This dedication to patient-centric solutions underscores MannKind's ambition to make a transformative impact in the evolving healthcare landscape.